These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 14602458)

  • 1. HER2 and proliferation of wound-induced breast carcinoma.
    Mannello F; Papa S
    Lancet; 2003 Nov; 362(9394):1503-4. PubMed ID: 14602458
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of HER2 in wound-induced breast carcinoma proliferation.
    Tagliabue E; Agresti R; Carcangiu ML; Ghirelli C; Morelli D; Campiglio M; Martel M; Giovanazzi R; Greco M; Balsari A; Ménard S
    Lancet; 2003 Aug; 362(9383):527-33. PubMed ID: 12932384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 and proliferation of wound-induced breast carcinoma.
    Tez M; Göçmen E; Ozçelik T
    Lancet; 2003 Nov; 362(9394):1503; author reply 1503. PubMed ID: 14602459
    [No Abstract]   [Full Text] [Related]  

  • 4. HER2 and surgery: more questions to answer.
    Spigel DR
    Lancet; 2003 Aug; 362(9383):502-3. PubMed ID: 12932377
    [No Abstract]   [Full Text] [Related]  

  • 5. [ERBB2/HER2: from molecular to clinical oncology].
    Khanson KP; Imianitov EN
    Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
    [No Abstract]   [Full Text] [Related]  

  • 6. What is the ideal HER2 test for Herceptin therapy?
    Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
    [No Abstract]   [Full Text] [Related]  

  • 7. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
    Perez EA; Roche PC; Jenkins RB; Reynolds CA; Halling KC; Ingle JN; Wold LE
    Mayo Clin Proc; 2002 Feb; 77(2):148-54. PubMed ID: 11838648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).
    van de Vijver MJ
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S11-7. PubMed ID: 11167086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 10. The HERstory of breast cancer revealed.
    Sledge GW
    Clin Breast Cancer; 2003 Dec; 4(5):308. PubMed ID: 14715104
    [No Abstract]   [Full Text] [Related]  

  • 11. [Breast cancer].
    Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
    Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
    Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 testing.
    Horten B; Da Silva M; Thompson J
    CAP Today; 2001 Jan; 15(1):8-9. PubMed ID: 11317560
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines.
    Kauraniemi P; Hautaniemi S; Autio R; Astola J; Monni O; Elkahloun A; Kallioniemi A
    Oncogene; 2004 Jan; 23(4):1010-3. PubMed ID: 14647448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
    Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
    J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiangiogenic agents in breast cancer.
    Salter JT; Miller KD
    Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
    [No Abstract]   [Full Text] [Related]  

  • 18. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
    Whenham N; D'Hondt V; Piccart MJ
    Clin Breast Cancer; 2008 Feb; 8(1):38-49. PubMed ID: 18501058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.
    Montemurro F; Aglietta M
    Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysomy 17 and HER-2 amplification: true, true, and unrelated.
    Rosenberg CL
    J Clin Oncol; 2008 Oct; 26(30):4856-8. PubMed ID: 18794542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.